Friday, October 1, 2021

A Hospital Gives Its Staff Panic Buttons After Assaults By Patients Triple September 30, 2021 DEEPA SHIVARAM

 HEALTH CARE

A Hospital Gives Its Staff Panic Buttons After Assaults By Patients Triple

Cox Medical Center in Branson, Mo., is implementing a personal panic button system for hundreds of its employees. Assaults of hospital staff tripled from 2019 to 2020, the hospital says.

Brandei Clifton/Cox Medical Center

Nurses and other staff at a hospital in Missouri have experienced such a surge in assaults from patients that they will have a panic button system installed on their badges allowing them to alert hospital security more easily if they are in danger.

Between 2019 and 2020, assaults by patients tripled at the Cox Medical Center in Branson, Mo. Last year, 123 attacks against hospital staff were reported — up from 40 in 2019. Injuries related to the assaults jumped from 17 to 78 during the same period.

"That kind of raised a red flag that we need to get some extra protection in place," Brandei Clifton, the hospital's communications manager, told NPR. "Until these buttons are implemented, right now, a nurse either has to call security on her phone or scream for help, and so this is an extra easy way they can get immediate response."

During the pandemic, patients have been frustrated because they've had to wait longer to be seen and visitors have been upset they can't see their loved ones, Clifton said.

Clifton said that nurses have been "really grateful" the new system is coming. The hospital is hoping the system — which will be installed before the end of the year — will encourage more nurses to report incidents of verbal or physical violence. Many incidents currently go underreported.

"We want nurses to report everything," Clifton said, from a patient cussing them out to having a meal tray thrown at them.

The hospital said about 300 to 400 staff working in the emergency department and inpatient hospital rooms will have access to their personal panic buttons. If the button is pushed, it activates a personal tracing system, security is notified and an alert on hospital computers shows the employee's location.

Funding to implement the panic button system comes from a grant of more than $132,000 from a local charity, the Skaggs Foundation, which helps provide funding for medical projects in the region.

The panic button system was implemented last year at a nearby hospital, Cox Springfield. That hospital said the system has decreased security response time.

The pandemic has added to more workplace violence for health care workers

Since the pandemic, there's been a spike in assaults on health care workers all over the country.

The Associated Press reported that health care workers in Idaho were hesitant to be seen anywhere in public, at places such as the grocery store, in their scrubs, and have faced verbal and physical assaults.

study published last month showed nurses who took care of patients with COVID-19 were more likely to experience verbal and physical assaults. One in 10 nurses, the study said, found it more difficult to report these incidents during the pandemic.

The workplace violence health care workers experience is an issue that's been ongoing since even before the pandemic. Data from the U.S. Bureau of Labor Statistics showed that health care workers and those who work in social assistance are five times more likely to experience workplace violence than other workers.

To be clear, those instances skew toward psychiatric and substance abuse hospitals, which saw far greater rates of injury than other hospitals and health care settings.

Faster security response time has its limits

Some experts warn that such panic buttons aren't a complete solution. They don't necessarily prevent assaults.

Some hospitals' data has also shown the racial disparities of calling hospital security.

At Seattle Children's Hospital, security was called on Black families twice as often as white families. A 2017 study from the University of Michigan also showed that hospital security was called on Black patients and visitors twice as often as other patients despite Blacks making up only 12% of the hospital population.

A pill can reduce deaths by half in new coronavirus patients, company says October 1, 2021 THE ASSOCIATED PRESS

 HEALTH

A pill can reduce deaths by half in new coronavirus patients, company says

Merck & Co. shows their new antiviral medication. Pharmaceutical company Merck & Co. announced Friday, that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.

Merck & Co. /AP

WASHINGTON — Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.

If cleared, Merck's drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.

Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease.

Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck. The results were released by the company and have not been peer reviewed. Merck said it plans to present them at a future medical meeting.

An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. Company executives said they are in discussions with the Food and Drug Administration and plan submit the data for review in coming days.

"It exceeded what I thought the drug might be able to do in this clinical trial," said Dr. Dean Li, vice president of Merck research. "When you see a 50% reduction in hospitalization or death that's a substantial clinical impact."

Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.

Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to given by IV or injection at hospitals or medical clinics, and supplies have been stretched by the latest surge of the delta variant.

Health experts including the top U.S. infectious disease expert Dr. Anthony Fauci have long called for a convenient pill that patients could take when COVID-19 symptoms first appear, much the way the decades-old flu medication Tamiflu helps fight influenza. Such medications are seen as key to controlling future waves of infection and reducing the impact of the pandemic.

Merck's pill works by interfering with an enzyme the coronavirus uses to copy its genetic code and reproduce itself. It has shown similar activity against other viruses.

The U.S. government has committed to purchase 1.7 million doses of the drug if it is authorized by the FDA. Merck has said it can produce 10 million doses by the end of the year and has contracts with governments worldwide. The company has not announced prices.

Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.

Merck had planned to enroll more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe and Africa. Executives estimated about 10% of patients studied were from the U.S.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

Contact Form

Name

Email *

Message *